Plain-English translation of NCT06573411 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether finerenone, a new medication, can help people with primary membranous nephropathy (a kidney disease that causes too much protein to leak into the urine) when added to their current standard treatment. Half of participants will continue their standard kidney medicine alone, while the other half will also take finerenone. The study wants to see if this medication helps protect the kidneys better and is safe to use.
Primary membranous nephropathy is a serious kidney condition where the body's immune system damages the kidney's filtering units, causing dangerous protein loss. Even with current standard treatments, many patients continue to lose too much protein and develop worsening kidney disease. This medication may offer an additional way to protect kidney function and reduce protein loss.
You likely qualify if…
You likely don't qualify if…
You will continue taking your current standard kidney medication at the highest dose you can tolerate. You will then be randomly assigned to either keep taking only that standard medication, or to also take finerenone 20 mg once daily. Throughout the study, you will have regular visits to check your blood pressure, kidney function tests, and urine protein levels to see how the treatment is working and whether it is safe.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
China